文献速递主动脉疾病

二甲双胍处方与腹主动脉瘤生长速率降低及趋化因子表达减少相关:瑞典队列研究

Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort.
PubMed 文献 · Ann Vasc Surg · 2020-06-30

该瑞典多中心队列研究纳入526例小腹主动脉瘤监测患者,分析二甲双胍处方与AAA生长速率的关系,并对240例AAA患者及59例对照检测40种炎症趋化因子。结果显示二甲双胍处方与AAA生长速率降低显著相关,且与代表各类白细胞的趋化因子表达减少相关,但无二甲双胍处方的2型糖尿病无此关联。

要点

  • 二甲双胍处方与AAA年生长速率降低显著相关,独立于2型糖尿病本身。
  • 二甲双胍处方与代表所有白细胞类别的趋化因子表达减少相关。
  • 无二甲双胍处方的2型糖尿病与AAA生长速率无显著关联。

核心结论

  • 二甲双胍处方与AAA生长速率降低相关,可能由广泛抗炎效应介导。
  • 需随机对照试验确定二甲双胍在AAA疾病中的作用,尤其在不伴2型糖尿病时。

研究设计与样本

  • 在4个瑞典血管中心识别小AAA监测患者,记录年AAA生长速率、病史和处方药物进行线性回归分析。
  • 526例患者纳入AAA生长分析:428例无2型糖尿病,65例有2型糖尿病且处方二甲双胍,33例有2型糖尿病但未处方二甲双胍。
  • 患者纳入时间为2005至2017年,平均随访3.2(1.7)年,中位年AAA生长速率1.6 mm,范围-4.8至15.4 mm。
  • 240例AAA患者(152例无2型糖尿病,51例有2型糖尿病且用二甲双胍,37例有2型糖尿病但未用二甲双胍)和59例无AAA或2型糖尿病对照者检测血浆40种炎症趋化因子。

主要发现

  • 非2型糖尿病患者的平均年AAA生长速率为2.3(2.2)mm,有2型糖尿病且处方二甲双胍者为1.1(1.1)mm,有2型糖尿病但未处方二甲双胍者为1.6(1.4)mm。
  • 以非2型糖尿病为参照,在未调整和2个调整模型中,二甲双胍处方与AAA生长速率降低显著相关(P < 0.001,P = 0.005,P = 0.024)。
  • 有2型糖尿病但未处方二甲双胍与AAA生长速率无显著关联(P = 0.137,P = 0.331,P = 0.479)。
  • 二甲双胍处方与代表所有白细胞类别的趋化因子表达减少相关。

临床怎么用

  • 对于小AAA监测患者,二甲双胍处方可能与较慢的AAA生长相关,但需随机对照试验验证。
  • 不应仅基于本观察性研究结果改变AAA患者的二甲双胍处方实践。

局限性

  • 为观察性队列研究,无法确立因果关系。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent reports suggest that the negative association between diabetes mellitus and abdominal aortic aneurysm (AAA) may be driven by metformin, the world's most common antidiabetic drug rather than diabetes per se. We sought to investigate the association among AAA growth rate, chemokine profile, and metformin prescription in a contemporary Swedish cohort. METHODS: Patients under surveillance for small AAA were identified at 4 Swedish vascular centers with active AAA screening programs. Annual AAA growth rate, medical history, and prescribed medications were recorded for linear regression analysis. In a subset of patients with AAA and control subjects without AAA or diabetes, plasma samples were available and analyzed for 40 inflammatory chemokines. RESULTS: A total of 526 patients were included for AAA growth analysis: 428 without type 2 diabetes mellitus (T2DM), 65 with T2DM and metformin prescription, and 33 with T2DM but without metformin prescription. Patients were included from 2005 to 2017 with mean follow-up of 3.2 (1.7) years and median annual AAA growth rate 1.6 mm, range -4.8 to 15.4 mm. Mean (standard deviation) annual AAA growth rates were 2.3 (2.2) mm in non-T2DM patients versus 1.1 (1.1) mm in patients with T2DM with metformin prescription and 1.6 (1.4) mm among those with T2DM without metformin prescription. With non-T2DM patients as reference in an unadjusted and 2 adjusted models, metformin prescription was significantly associated with reduced AAA growth rate (P < 0.001, P = 0.005, and P = 0.024, respectively), but not T2DM without metformin prescription (P = 0.137, P = 0.331, and P = 0.479, respectively). Among 240 patients with AAA (152 without T2DM, 51 with T2DM and metformin, and 37 with T2DM without metformin) and 59 without AAA or T2DM, metformin prescription was associated with reduced expression of chemokines representing all classes of leukocytes. CONCLUSIONS: Metformin prescription is associated with reduced AAA growth rate, possibly mediated by broad anti-inflammatory effects. A randomized controlled trial is needed to determine what role metformin may play in AAA disease, particularly in the absence of T2DM.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Unosson J, Wågsäter D, Bjarnegård N, et al. Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort. Ann Vasc Surg. 2020. PMID: 32619497. doi:10.1016/j.avsg.2020.06.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。